NuCana Achieves Nasdaq Compliance and Secures Cash Runway into 2029

Nucana ( (NCNA) ) has issued an announcement.

On September 5, 2025, NuCana announced its compliance with Nasdaq’s continued listing criteria, including the $1.00 minimum bid price requirement, following a notification from Nasdaq on September 4, 2025. This compliance marks the closure of a previously disclosed listing issue. The company, having secured a strong cash position, anticipates its resources will support operations into 2029, allowing it to pursue key milestones in its mission to enhance cancer treatment outcomes.

The most recent analyst rating on (NCNA) stock is a Buy with a $20.00 price target. To see the full list of analyst forecasts on Nucana stock, see the NCNA Stock Forecast page.

Spark’s Take on NCNA Stock

According to Spark, TipRanks’ AI Analyst, NCNA is a Underperform.

Nucana’s overall score is primarily impacted by its financial instability and negative valuation metrics. The significant lack of revenue generation and operational losses are major concerns. Despite showing strong cash management and low leverage, the company’s technical indicators suggest a bearish trend, further weighing down the score. The poor valuation metrics, such as a negative P/E ratio, are offset by potential speculative interest due to the low stock price. The absence of notable earnings call insights or corporate events means these factors did not influence the score.

To see Spark’s full report on NCNA stock, click here.

More about Nucana

NuCana is a clinical-stage biopharmaceutical company focused on improving cancer treatment outcomes by applying its proprietary ProTide technology. This technology aims to transform widely used chemotherapy agents, nucleoside analogs, into more effective and safer medicines. NuCana’s pipeline includes NUC-7738 and NUC-3373, which are being evaluated in clinical studies for various cancer treatments.

Average Trading Volume: 1,162,086

Technical Sentiment Signal: Sell

Current Market Cap: $5.46M

See more data about NCNA stock on TipRanks’ Stock Analysis page.